What Has Been The Evolution of the Candidiasis Therapeutics Market in Recent Years?
The candidiasis therapeutics market has seen considerable growth due to a variety of factors.
• The market size for candidiasis therapeutics has been experiencing a consistent growth over the past few years. It is projected to expand from $3.19 billion in 2024 to $3.3 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 3.4%.
Factors contributing to the growth during the historical time frame include a rise in the occurrences of candidiasis, the use and resistance to antibiotics, infections acquired in hospitals, changes in fungal resistance trends and awareness and educational initiatives.
What Are the Future Growth Projections for the Candidiasis Therapeutics Market?
The candidiasis therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size of candidiasis therapeutics is projected to consistently increase, reaching $3.83 billion by 2029 at a compound annual growth rate (CAGR) of 3.8%.
This anticipated growth during the forecast period can be ascribed to the use of precision medicine techniques, global stewardship programs for antifungal treatments, a rise in cases of candida auris, and worldwide initiatives to combat antifungal resistance. Key trends predicted for the forecast period include advancements in drug delivery systems, the utilization of telemedicine and remote patient tracking, patient-centered care, combination therapies, and cooperative research endeavours.
What Are The Core Factors Supporting Growth In The Candidiasis Therapeutics Market?
The anticipated surge in the incidence of fungal infections is poised to stimulate the expansion of the candidiasis therapeutics market. Fungal infections are diseases triggered by various kinds of fungi, which can invade the skin, mucosal surfaces, and internal organs. The mounting number of individuals with weakened immune systems combined with those suffering from fungal infections heightens the likelihood of candidiasis. This reality presents opportunities for drug manufacturers to design and distribute highly specialized and efficacious antifungal medicines that specifically target the causative fungi. These drugs aim to alleviate symptoms, prevent further complications, hasten patient recovery, limit the transmission of Candida infections within healthcare settings, and enhance patient prognosis. For example, the University of Minnesota, a prominent research university in the US, stated in January 2024 that more than 3.75 million deaths are caused by fungal infections each year, with roughly 2.55 million of these deaths directly resulting from fungal diseases. Therefore, the increasing frequency of fungal infections is projected to be a significant driving factor for the candidiasis therapeutics market advancement. Candidiasis Therapeutics Market Driver: Escalation of Clinical Trials Promoting Advances in Candidiasis Therapeutics Market
What Are The Major Segments Within The Global Candidiasis Therapeutics Market?
The candidiasis therapeutics market covered in this report is segmented –
1) By Treatment Type: Medication, Surgery, Other Treatments
2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis
3) By Mode Of Administration: Injectable, Oral, Other Mode Of Administrations
4) By Patient Population: Adults, Pediatrics
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Antifungal Drugs, Topical Treatments, Systemic Treatments
2) By Surgery: Surgical Debridement, Organ Removal
3) By Other Treatments: Probiotics, Home Remedies, Lifestyle Modifications
Pre-Book The Candidiasis Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Candidiasis Therapeutics Market?
Key players in the candidiasis therapeutics market, such as Scynexis Inc., are generating innovative solutions, including BREXAFEMME (ibrexafungerp tablets), aimed at decreasing the rate of recurrent vulvovaginal candidiasis (RVVC) among adult women. BREXAFEMME, a non-azole oral medication, has been designed for treating vulvovaginal candidiasis (VVC) and curbing the frequency of RVVC, often referred to as chronic yeast infections. Scynexis Inc., a pharmaceutical company based in the US, received approval from the US Food and Drug Administration (FDA) for this novel drug in December 2022. The primary working mechanism of BREXAFEMME is the inhibition of the Candida albicans, the fungal pathogen behind VVC. In addition, BREXAFEMME is both a safe and effective cure for vulvovaginal candidiasis and can only be procured through a prescription. The proposed dosage is a single 150-mg capsule consumed orally once a day for one day.
Who Are the Key Players In The Candidiasis Therapeutics Market?
Major companies operating in the candidiasis therapeutics market report are:
• Pfizer Inc.
• Biocon Limited
• Torrent Pharmaceuticals Ltd.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• AstraZeneca plc.
• GSK plc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Cipla Inc.
• Bruker Corporation
• Lupin Limited
• Galapagos NV
• Basilea Pharmaceutica Ltd.
• WOCKHARDT Limited
• Pacgen Life Science Corporation
• Cidara Therapeutics Inc.
• Ablynx NV
• Amplyx Pharmaceuticals Inc.
• NovaDigm Therapeutics Inc.
• SCYNEXIS Inc.
• Medivir AB
• Mycovia Pharmaceuticals Inc.
• NovaBiotics Inc.
• Matinas BioPharma Holdings Inc.
What Is The Most Dominant Region In The Candidiasis Therapeutics Market?
North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
